ERBB2 and breast carcinoma: In the PERTAIN trial [54], it was hypothesized that pertuzumab, trastuzumab, and an endocrine-therapy (aromatase inhibitor) may offer additional benefits compared with trastuzumab plus an aromatase inhibitor for HER2–positive and hormone receptor–positive MBC or locally advanced breast cancer (LABC) in first line.